Jeffrey P. Mornhinweg

Array ( [id] => 18700090 [patent_doc_number] => 11786577 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => HIV treatment compositions and methods [patent_app_type] => utility [patent_app_number] => 17/475783 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 18 [patent_no_of_words] => 11251 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17475783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343640 [patent_doc_number] => 20220009971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom [patent_app_type] => utility [patent_app_number] => 17/474732 [patent_app_country] => US [patent_app_date] => 2021-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17474732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18717862 [patent_doc_number] => 11795193 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Manufacturing optimization of GL-2045, a multimerizing stradomer [patent_app_type] => utility [patent_app_number] => 17/474144 [patent_app_country] => US [patent_app_date] => 2021-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 65 [patent_no_of_words] => 30840 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17474144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855748 [patent_doc_number] => 12258572 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Adenovirus vectors and methods for using adenovirus vectors [patent_app_type] => utility [patent_app_number] => 17/469569 [patent_app_country] => US [patent_app_date] => 2021-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 202 [patent_figures_cnt] => 86 [patent_no_of_words] => 18087 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17469569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441905 [patent_doc_number] => 20220062410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => USE OF ENDOGENOUS VIRAL VACCINE IN CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY [patent_app_type] => utility [patent_app_number] => 17/465728 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18647892 [patent_doc_number] => 20230293670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => NOVEL CORONAVIRUS RECOMBINANT SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING SAME, VECTOR COMPRISING POLYNUCLEOTIDE, AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION, COMPRISING VECTOR [patent_app_type] => utility [patent_app_number] => 18/042913 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18647892 [patent_doc_number] => 20230293670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => NOVEL CORONAVIRUS RECOMBINANT SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING SAME, VECTOR COMPRISING POLYNUCLEOTIDE, AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION, COMPRISING VECTOR [patent_app_type] => utility [patent_app_number] => 18/042913 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297931 [patent_doc_number] => 20210393770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => ADENOVIRAL VECTORS ENCODING HEPATITIS B VIRAL ANTIGENS FUSED TO HERPES VIRUS GLYCOPROTEIN D AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/459313 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17459313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18647892 [patent_doc_number] => 20230293670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => NOVEL CORONAVIRUS RECOMBINANT SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING SAME, VECTOR COMPRISING POLYNUCLEOTIDE, AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION, COMPRISING VECTOR [patent_app_type] => utility [patent_app_number] => 18/042913 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18947064 [patent_doc_number] => 11890337 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-06 [patent_title] => VLP-based bivalent ebola vaccines and methods of making and using same [patent_app_type] => utility [patent_app_number] => 17/411097 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6707 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379400 [patent_doc_number] => 20240269270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => COVID-19 VACCINES WITH TOCOPHEROL-CONTAINING SQUALENE EMULSION ADJUVANTS [patent_app_type] => utility [patent_app_number] => 18/042637 [patent_app_country] => US [patent_app_date] => 2021-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748292 [patent_doc_number] => 20220226495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION [patent_app_type] => utility [patent_app_number] => 17/404908 [patent_app_country] => US [patent_app_date] => 2021-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17404908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657684 [patent_doc_number] => 20230303629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => FUSION PROTEINS COMPRISING SARS-COV-2 NUCLEOCAPSID DOMAINS [patent_app_type] => utility [patent_app_number] => 18/020797 [patent_app_country] => US [patent_app_date] => 2021-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6303 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18020797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17815649 [patent_doc_number] => 11421248 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Temperature-based transient delivery of nucleic acids and proteins to cells and tissues [patent_app_type] => utility [patent_app_number] => 17/404901 [patent_app_country] => US [patent_app_date] => 2021-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 37 [patent_no_of_words] => 31491 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17404901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18724373 [patent_doc_number] => 20230338516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => RECOMBINANT POXVIRIDAE VECTOR EXPRESSING CO-STIMULATORY MOLECULES [patent_app_type] => utility [patent_app_number] => 18/005291 [patent_app_country] => US [patent_app_date] => 2021-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18978858 [patent_doc_number] => 11904012 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-20 [patent_title] => Modification of engineered influenza hemagglutinin polypeptides [patent_app_type] => utility [patent_app_number] => 17/400390 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 15 [patent_no_of_words] => 28114 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 208 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292193 [patent_doc_number] => 20210388032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES [patent_app_type] => utility [patent_app_number] => 17/387105 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 117508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17229909 [patent_doc_number] => 20210356466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => Rapid Viral Assay [patent_app_type] => utility [patent_app_number] => 17/379370 [patent_app_country] => US [patent_app_date] => 2021-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17379370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17241985 [patent_doc_number] => 20210361728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => CANCER IMMUNOTHERAPY USING VIRUS PARTICLES AND IMMUNE CHECKPOINT THERAPY [patent_app_type] => utility [patent_app_number] => 17/369405 [patent_app_country] => US [patent_app_date] => 2021-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17369405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18383425 [patent_doc_number] => 11654189 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Compositions and methods for enhancing the stability of transgenes in poxviruses [patent_app_type] => utility [patent_app_number] => 17/367528 [patent_app_country] => US [patent_app_date] => 2021-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 21 [patent_no_of_words] => 17828 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367528 [rel_patent_id] =>[rel_patent_doc_number] =>)